A positive correlation between response and PD-L1 levels was reported in GeparNuevo in the overall group (phase II trial of neoadjuvant durvalumab combined with nab-paclitaxel followed by epirubicin plus cyclophosphamide); however, this was not specific to durvalumab (the pCR rate in PD-L1-positive tumours was 58% versus 44.4% in the PD-L1-negative group (p = 0.445)) [75]. This evidence concerns the gene CD274 and neoplasm.